Correction: Iambic says new AI model bests AlphaFold as protein models rocket ahead
The second-generation of Iambic Therapeutics’ AI model that predicts the combined shape of proteins and small molecules outperforms Google DeepMind’s AlphaFold, the San Diego biotech’s leaders told Endpoints News.
The claim comes in a new whitepaper, alongside a Nature Machine Intelligence publication with Nvidia and Caltech researchers about the first-gen version.
The field has grown increasingly crowded, competitive and commercially focused since the July 2021 publication of AlphaFold. Beyond AlphaFold and Iambic’s model, CHARM Therapeutics launched in 2022 to develop DragonFold, a rival model developed by CEO Laksh Aithani and University of Washington’s David Baker. These tools have also attracted Big Pharma’s attention, with Bristol Myers Squibb partnering with CHARM and Eli Lilly and Novartis both signing deals with Isomorphic last month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
